Goldman Sachs’s Rubius Therapeutics, Inc RUBY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-17,511
| Closed | -$3.06K | – | 5416 |
|
|
2022
Q4 | $3.06K | Sell |
17,511
-27,010
| -61% | -$4.73K | ﹤0.01% | 5036 |
|
|
2022
Q3 | $19K | Sell |
44,521
-234,387
| -84% | -$100K | ﹤0.01% | 5184 |
|
|
2022
Q2 | $238K | Sell |
278,908
-105,845
| -28% | -$90.3K | ﹤0.01% | 4821 |
|
|
2022
Q1 | $2.12M | Sell |
384,753
-18,088
| -4% | -$99.7K | ﹤0.01% | 3542 |
|
|
2021
Q4 | $3.9M | Buy |
402,841
+30,222
| +8% | +$293K | ﹤0.01% | 3004 |
|
|
2021
Q3 | $6.66M | Buy |
372,619
+206,659
| +125% | +$3.69M | ﹤0.01% | 2581 |
|
|
2021
Q2 | $4.05M | Buy |
165,960
+69,809
| +73% | +$1.7M | ﹤0.01% | 2948 |
|
|
2021
Q1 | $2.55M | Sell |
96,151
-9,354
| -9% | -$248K | ﹤0.01% | 3175 |
|
|
2020
Q4 | $801K | Sell |
105,505
-39,090
| -27% | -$297K | ﹤0.01% | 3575 |
|
|
2020
Q3 | $724K | Buy |
144,595
+24,598
| +20% | +$123K | ﹤0.01% | 3489 |
|
|
2020
Q2 | $718K | Buy |
119,997
+21,220
| +21% | +$127K | ﹤0.01% | 3413 |
|
|
2020
Q1 | $440K | Buy |
98,777
+7,167
| +8% | +$31.9K | ﹤0.01% | 3556 |
|
|
2019
Q4 | $871K | Buy |
91,610
+24,589
| +37% | +$234K | ﹤0.01% | 3400 |
|
|
2019
Q3 | $526K | Buy |
67,021
+4,486
| +7% | +$35.2K | ﹤0.01% | 3574 |
|
|
2019
Q2 | $984K | Buy |
62,535
+11,330
| +22% | +$178K | ﹤0.01% | 3201 |
|
|
2019
Q1 | $927K | Buy |
51,205
+15,395
| +43% | +$279K | ﹤0.01% | 3296 |
|
|
2018
Q4 | $576K | Buy |
+35,810
| New | +$576K | ﹤0.01% | 3360 |
|